Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Children With Attention-deficit/Hyperactivity Disorder (ADHD)
Key Details
Gender
All
Age Range
4 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
574
Start Date
2022-07-11
Completion Date
2025-03-17
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
centanafadine capsule
capsule
placebo capsule
capsule
Locations (1)
For additional information regarding sites, contact 844-687-8522
New York, New York, United States